The OncLive COVID-19 condition center page is a comprehensive resource for clinical news and expert insights on how the COVID-19 pandemic has impacted multiple areas of oncology care and practice. This page features news articles, interviews in written and video format, and podcasts encompassing data of patients with COVID-19 and cancer, oncology drugs being tested against the virus, vaccine information for patients with cancer, and more.
Reaching Conclusions From Limited Data Holds PitfallsMay 13th 2021
The challenges of assessing COVID-19 vaccines shows that events in the real world may differ from those of a formal objective scientific analysis, especially in a setting where such evaluations of necessity involve very small numbers.
Missteps Highlight the Need for Objectivity in ScienceApril 30th 2021
Although the spectacular success associated with the development of several safe and highly efficacious vaccines and therapies for COVID-19 has once again confirmed the remarkable impact of advancements on public and individual health, we must also acknowledge recent stunning examples of the failure of scientifically oriented government agencies to provide objectively valid nonpolitical recommendations, policies, and conclusions.
Risk-Based Triaged Mammograms Demonstrate Success During Periods of Reduced CapacityApril 28th 2021
Triaging individuals with the highest likelihood of cancer detection with their clinical indication and individual risk factors during periods of reduced capacity could be an efficient way of identifying the most cancers with the least examinations compared with a non–risk-based approach.
CCC19 Updates Uncover High All-Cause Mortality in Patients With COVID-19 and Cancer Receiving Select ChemotherapiesApril 21st 2021
Patients with cancer who have contracted COVID-19 trend towards having high disease severity and mortality, especially among those with select demographic and clinical characteristics, with certain chemotherapy regimens contributing towards a high all-cause mortality.
Tocilizumab May Have Activity Against COVID-19–Associated Cytokine Storm in Myeloma
Tocilizumab may represent a potential treatment option with double action against cytokine storm due to COVID-19 in a subset of patients with active multiple myeloma and severe infection with the virus.
Clinical Progress Creates Need for Decision-Support ToolsApril 20th 2021
The current endorsement of 3 COVID-19 vaccines in the United States, with several additional products pending FDA review, in less than 1 year from the identification of the structure of the COVID-19 virus is simply remarkable.
COVID-19 Jumpstarts RNA Cancer Vaccine Field
The success of the COVID-19 vaccines based on messenger RNA has led to a surge of interest from investigators, pharmaceutical companies, and investors in similar technology for other diseases, including a number of oncology indications.
Matsen Spotlights Best Practices for Breast Cancer Surgery Amidst the COVID-19 CrisisApril 7th 2021
The coronavirus disease 2019 pandemic had a tremendous impact on the surgical care of patients with breast cancer; practice patterns needed to be rapidly adjusted to continue to safely provide care during a time when resources were very limited.
COVID-19 Has Lessons for Oncology Clinical TrialsApril 5th 2021
The coronavirus disease 2019 pandemic required that investigators, sponsors, and regulators adapt clinical trials to prioritize the safety of patients. Now momentum is gathering to make permanent the flexibilities introduced in regulations and procedures to improve access to clinical trials for patients with cancer.
COVID-19 and Cancer Care: Lessons Learned 1 Year LaterMarch 31st 2021
From delayed diagnoses, to the emergence of telemedicine, to managing the increased emotional burden experienced by patients and healthcare professionals alike, the community has been forced to approach cancer care in ways they never had before in light of the COVID-19 pandemic.
The COVID-19 Pandemic Will Have Long-Term Impact on Oncology PracticesMarch 29th 2021
The COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.